Patents

AbbVie California
Pharmalot

Consumer groups and unions urge FTC to block AbbVie and Allergan merger

By Ed Silverman

Medication and money
First Opinion

Patent reform is needed to protect patients’ access to lifesaving drugs

By Lyrissa Lidsky

Pharmalot

Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on

By Ed Silverman

Sen. Thom Tillis
First Opinion

Proposed patent legislation would block research, stifle innovation, and harm patients

By Othman Laraki

Alex Brandon/AP
Pharmalot

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

By Ed Silverman

JOHNSON & JOHNSON HEADQUARTERS
Pharmalot

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

By Ed Silverman

Pharmalot

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

By Ed Silverman

Pharmalot

Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers

By Ed Silverman

Pharmalot

Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament

By Ed Silverman

Bristol-Myers Squibb
Pharmalot

Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying

By Ed Silverman

Colorful book shelf
First Opinion

We need a Public Domain Day to highlight when drugs go off patent

By Peter Kolchinsky and Jessica Sagers

Humira
Pharmalot

AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument

By Ed Silverman

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

Pharmalot

Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again

By Ed Silverman

Drug costs
Pharmalot

Trump administration report would preclude reclaiming patents as a way to lower drug prices

By Ed Silverman

Pharmalot

Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices

By Ed Silverman

Pharmalot

Supreme Court to decide a patent case with big implications for small drug makers

By Ed Silverman

Pharmalot

Pharmalittle: AbbVie cancer program’s setback; Amazon hires a pharmacy expert

By Ed Silverman

German Pharma
Pharmalot

Boehringer Ingelheim abandons biosimilar sales outside the U.S.

By Ed Silverman

Pharmalot

Pharmalittle: D.C. law firms prep pharma for a Democratic house; Allergan loses another battle over Restasis patent deal

By Ed Silverman

Pharmalot

Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment

By Ed Silverman

Tuberculosis patient
Pharmalot

U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise

By Ed Silverman

Pharmalot

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug

By Ed Silverman

Pharmalot

With a push from pharma, U.S. Trade Rep pressure on Colombia starts to take hold

By Ed Silverman

Gilead Sciences
Pharmalot

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

By Ed Silverman

NIH headquarters
Pharmalot

NIH is urged to probe Aegerion patents for failing to disclose federal funding

By Ed Silverman

Hepatitis C
Pharmalot

Tens of millions of people continue to lack access to hepatitis C medicines

By Ed Silverman

Gilead Sciences
Pharmalot

HHS is urged to investigate a Gilead hepatitis C patent for failing to disclose federal funding

By Ed Silverman

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy